Natera Inc (NTRA)

Industry Diagnostics & Research
This stock can be held in an Investment ISA and an Investment Account
Sell

$157.33

Buy

$157.89

arrow-up$5.75 (+3.78%)

Natera Inc is a provider of diagnostic services predominantly in the United States. It offers various tests which detect chromosomal abnormalities, reasons for miscarriages and paternity.
Prices updated at 12 May 2025, 15:17 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up3.35%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Diagnostics & Research
Chairman
Dr. Matthew Rabinowitz
CEO
Mr. Steven Leonard Chapman
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
4,434
Head office
13011 McCallen Pass
Austin
United States
78753
mobile
+1 650 980-9190
letter
mbrophy@natera.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Dr. Monica Bertagnolli, M.D.
Independent Director
-----
Mr. Herm Rosenman
Independent Director
0.09m--0.45m-
Dr. James I. Healy, M.D.,PhD
Independent Director
0.08m--0.40m-
Ms. Ruth W. Brinkley
Independent Director
-----
Mr. Roelof Frederik Botha
Lead Independent Director
0.10m--0.47m-
Dr. Matthew Rabinowitz
Executive Chairman of the Board
0.40m--9.83m-
Mr. Jonathan Sheena
Director
-----
Dr. Roy D. Baynes, M.D.,PhD
Independent Director
0.06m--0.38m-
Mr. Michael Brophy
Chief Financial Officer and Principal Accounting Officer
0.49m--4.89m-
Dr. Gail B. Marcus
Independent Director
0.08m--0.45m-
Mr. Steven Leonard Chapman
Director, Chief Executive Officer and President
0.80m--13.03m-
Dr. Rowan E. Chapman, PhD
Independent Director
0.09m--0.45m-
Mr. Daniel Rabinowitz
Secretary and Chief Legal Officer
-----
Mr. Solomon Moshkevich
President, Clinical Diagnostics
0.49m--4.89m-
Mr. John Fesko
Co-President and Chief Business Officer
0.49m--4.89m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Vanguard Group Inc12,316,4700.033968794637.68962530 Apr 20259.06
BlackRock Inc9,180,4630.0294194745711.50803230 Apr 20256.75
T. Rowe Price Associates, Inc.6,742,4280.123043871862134.88148330 Apr 20254.96
JPMorgan Chase & Co6,701,4250.07899-2562633-27.662130 Apr 20254.93
T. Rowe Price5,244,32812.477281407664-30 Apr 20253.86

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
20 Dec 2024-Mr. Solomon Moshkevich--116,381--
23 Dec 2024-Mr. Solomon Moshkevich158.19475119,420--
23 Dec 2024-Mr. Solomon Moshkevich159.60386,721116,997--
23 Dec 2024-Mr. Solomon Moshkevich158.06316119,423--
20 Dec 2024-Mr. Solomon Moshkevich--119,425--
23 Dec 2024-Mr. John Fesko157.95158114,810--
23 Dec 2024-Mr. John Fesko159.60106,616114,142--
20 Dec 2024-Mr. John Fesko--114,811--
23 Dec 2024-Mr. Solomon Moshkevich--114,706--
19 Dec 2024-Mr. Solomon Moshkevich--114,787--
18 Dec 2024-Mr. Jonathan Sheena167.25305,231257,609--
18 Dec 2024-Mr. Jonathan Sheena168.0283,33946,282--
18 Dec 2024-Mr. Jonathan Sheena167.07142,34746,778--
18 Dec 2024-Mr. Jonathan Sheena166.0125,23347,630--
18 Dec 2024-Mr. Jonathan Sheena168.0450,91746,282--
18 Dec 2024-Mr. Jonathan Sheena167.18160,32546,585--
18 Dec 2024-Mr. Jonathan Sheena166.1839,55047,544--
18 Dec 2024-Mr. Jonathan Sheena168.1590,294257,072--
18 Dec 2024-Mr. Jonathan Sheena165.9756,099259,434--
13 Dec 2024-Dr. Matthew Rabinowitz168.35892,2802,389,180--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.